Milia: a useful clinical marker of CYLD mutation carrier status

Clin Exp Dermatol. 2018 Mar;43(2):193-195. doi: 10.1111/ced.13296. Epub 2017 Oct 12.

Authors

D S Bajwa^{1

2}, B Nasr³, A J Carmichael³, N Rajan^{1

2}

Affiliations

¹ Institute of Genetic Medicine, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.
² Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 3BZ, UK.
³ Department of Dermatology, James Cook University Hospital, Middlesbrough, North Yorkshire, UK.

PMID: 29023940
DOI: 10.1111/ced.13296

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Biomarkers, Tumor
Carcinoma, Adenoid Cystic / genetics
Deubiquitinating Enzyme CYLD / genetics*
Face / pathology
Female
Heterozygote*
Humans
Keratosis / genetics*
Male
Middle Aged
Mutation*
Pedigree

Substances

Biomarkers, Tumor
CYLD protein, human
Deubiquitinating Enzyme CYLD